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Overwhelmed Patients
A videographic analysis of how patients with type 2 diabetes and
clinicians articulate and address treatment burden during clinical
encounters
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OBJECTIVEdPatients with diabetes may experience high burden of treatment (BOT), in-
cluding treatment-related effects and self-care demands. We examined whether patients with
type 2 diabetes and their clinicians discuss BOT, the characteristics of their discussions, and
their attempts to address BOT during visits.
RESEARCHDESIGNANDMETHODSdTwo coders independently reviewed videos of
46 primary care visits obtained during a practice-based trial and identiﬁed utterances concerning
BOT, classifying them by topic and by whether BOT was addressed (i.e., whether statements
emerged aimed at alleviating BOT).
RESULTSdOf the 46 visits, 43 (93.5%) contained BOT discussions. Both coders identiﬁed 83
discussions: 12 involving monitoring, 28 treatment administration, 19 access, and 24 treatment
effects. BOT was unambiguously addressed only 30% of the time.
CONCLUSIONSdBOT discussions usually arise during visits but rarely beget problem-
solving efforts. These discussions represent missed opportunities for reducing treatment-related
disruptions in the lives of patients with diabetes, which may affect adherence and well-being.
Diabetes Care 35:47–49, 2012
Evidence-based medicine can imposehigh self-care demands on patientswith diabetes (1–4), negatively af-
fecting adherence and quality of life
(5–7). Little is known about how patient-
experienced burden of treatment (BOT)
(8–10) becomes articulated and ad-
dressed in routine clinical encounters,
where patients’ care needs are usually dis-
cussed (11–13). To understand these is-
sues, we analyzed videos of primary care
encounters between patients with type 2
diabetes and clinicians to assess the prev-
alence of BOT discussions, their charac-
teristics, and their efﬁcacy in generating
efforts to reduce BOT.
RESEARCH DESIGN
AND METHODS
Data
The Mayo Clinic Institutional Review
Board approved all procedures. Data con-
sisted of videos of clinical visits obtained
from both study arms of a randomized
trial (1) of a decision aid to help choose
antihyperglycemic agents (including in-
sulin), versus usual care, among 85 adults
with type 2 diabetes recruited from 11
primary care sites in Minnesota. Eligible
patients had diabetes for at least 1 year,
had poor glycemic control (HbA1c$7.0),
and were not on insulin. Videographic data
are useful for assessing patient-clinician
communication (13,14); we reviewed all
46 available videos for which patients and
clinicians gave written informed consent.
Analysis
We conducted quantitative content analy-
sis (15–19). Analytic categories, derived a
priori, were applied during coding, resem-
bling the directed or summative approaches
ofHsieh and Shannon (20). To reduce bias,
two authors (K.B. and E.S.) coded each
video.
On the basis of existing literature
(2,8,10), we deﬁned BOT as treatment-
related effects that limit the patient’s abil-
ity to participate in activities and tasks
that are crucial to his or her quality of
life and that are not attributable to under-
lying disease. We identiﬁed four analytic
domains of BOT for coding via team dis-
cussion based on literature (2,8,21) and
feedback from other experts: access, ad-
ministration, effects, and monitoring (see
Table 1).
BOT discussions were considered
addressed when they generated problem-
solving efforts by clinicians and/or patients,
including any statements regardingmethods
or strategies to alleviate BOT. No single
solutionhad tobe agreedondonly attempts
at reducing BOT. Coders used a standard
form to code videos and guide interrater
comparisons. No limit was set on the num-
ber of BOT discussions coded per video.
To optimize interrater reliability, cod-
ers completed a training analysis of sim-
ilar videos until they reached .90%
agreement. During this process, coders
discussed ambiguous situations and de-
veloped classiﬁcation rules to ensure con-
sistency. Finally, both coderswatched each
video, sometimes multiple times, to iden-
tify and classify BOT discussions.
Statistical analyses were generally de-
scriptive. Although sample size limited
their usefulness, where possible, we used
x2 tests and two-sample tests of propor-
tions (nominal signiﬁcance P , 0.05) us-
ing StataSE 11 (StataCorp, College Station,
TX) to test associations between discus-
sion characteristics.
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RESULTSdA total of 19 patients were
in the control arm (37% female, mean
age 63.5, mean visit length 21.3 min),
whereas 27 patients were in the decision
aid arm (56% female, mean age 61.5, visit
length 26.5 min).
Any BOT discussion
Initial interrater agreement on presence of
any BOT discussion was 85%. After con-
sensus, coders found 43 videos to contain
at least one discussion (16 control arm, 27
decision aid arm).
Number of discussions
Initially, 120 BOT discussions were
identiﬁed. Coders independently identi-
ﬁed 53 of the same discussions (3 were
coded in different domains, requiring
consensus). After reviewing the other 67
discussions, 30 were included through
consensus by both coders (ﬁnal total: 83
discussions).
Discussion characteristics
Patients initiated 55% of BOT discussions
(Table 1). Discussion initiator and trial arm
allocationwere signiﬁcantly associatedwith
domain (P = 0.035 and P = 0.031, respec-
tively). Only 30% of discussions were un-
ambiguously addressed.
CONCLUSIONSdOur results have
limitations. Although well suited to
descriptively studying discussions, sam-
ple size prevented further exploration
and meaningful statistical tests. Despite
coder training, some discussions re-
mained difﬁcult to code, and consensus
may not fully prevent categorization
errors. Work is needed to further develop
and validate BOT domains; rater bias may
interact with lack of clarity about what
constitutes BOT owing to sparse literature
on the subject.
At the time of the study, no validated
BOT tools existed. Domains were con-
structed a priori, but criteria evolved
during the training period. Current short-
comings in knowledge of BOT, including
poor understandings of patients’ experi-
ences, could be overcome via validated
measures and qualitative inquiry.
Because participants knew they were
being video recorded (and may have felt
compelled to speak more), BOT discus-
sionsmay have been overstated. Although
decision aids elicited more discussions
than usual care, this may reﬂect greater
visit length in this arm or a higher pro-
portion of women (as gendered interac-
tion patterns may affect discussions).
Design also may inject bias via trial eligi-
bility (insulin usersdexcluded heredmay
differ in articulations of BOT) and video
consent (consenters may be less burdened
or more responsive, although measured
characteristics showed little difference)
(1). Also, we examined discussions
within one visit; some may have been
addressed at subsequent visits to which
we have no access. Thus, results deserve
caution.
Despite limitations, the data offer im-
portant strengths and contributions. Rather
than surveys or other data removed from
clinical encounters, this study incorporated
direct observation of real primary care visits.
Discussions were recorded in real time
(negating the need for retrospection), and
participants were unaware of the purpose
of this substudy during visits.
Few studies address patients’ articu-
lations of BOT and/or clinician responses.
Our ﬁndings partially echo a previous
study, which ﬁnds that clinicians target
biomedical problems more than sociobe-
havioral factors, such as access or social
support (22). However, here, access was
prevalently addressed; administration
and monitoring, suggesting patients’ con-
cerns about day-to-day self-care demands,
were relatively unaddressed. In that pre-
vious study, concealed actors ensured
standardized scenarios. By contrast, we
studied uncontrolled encounters and so
were able to explore how BOTda patient-
experienced phenomenonddoes or does
not become articulated within clinical visits
for diabetes.
Table 1dDomains and characteristics of BOT discussions
Domain Deﬁnition Total
Party initiating Trial arm
BOT addressedPatient Provider
Decision aid
(n =27 patients)
Control
(n = 19 patients)
Access Patient’s efforts or difﬁculty
obtaining treatment in a
timely, convenient, or
affordable manner
19 (23) 7* (15) 11 (31) 15 (27) 4 (15) 9 (47)/2/8
Administration Burdens in correctly
delivering or taking
a treatment
28 (34) 20 (43) 8 (22)† 23 (41) 5 (19)† 2‡ (7)/9/17
Effects Unwanted or unintended
symptoms or consequences
of the prescribed treatment
24 (29) 10 (22) 14 (39) 12 (21) 12 (44)† 10 (42)/4/10
Monitoring Trouble complying with the
monitoring required for
effective or safe use of the
medication and following
its ongoing effects
12 (14) 9 (20) 3 (8) 6 (11) 6 (22) 4 (33)/1/7
Total 83 (100) 46 (100) 36 (100)† 57 (100) 27 (100) 25 (30)/16/42
x2 Association
with domain x2 = 8.61 P = 0.035 x2 = 8.89 P , 0.031 N/Aj
Data in BOT Addressed column are Yes, n (%)/Unclear, n/No, n; all other data n (%) unless otherwise noted. *One BOT discussion (not included) initiated by patient
spouse. †Percentage is signiﬁcantly different (P, 0.05) between groups (i.e., patient vs. clinician initiated and decision aid vs. control). ‡Administration was coded
“yes” (for being addressed) signiﬁcantly less (P , 0.05) than any other domain. jInsufﬁcient cell size for x2 comparison.
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Overwhelmed patients with diabetes
Patients with diabetes routinely dis-
cuss BOT with clinicians but often with
no effect. In the context of diabetes and
other chronic diseases, this represents lost
opportunities to offset preventable non-
adherence, costs, and poorer quality of
life for patients. As we progress toward
providing minimally disruptive medicine,
clinicians may need education on strate-
gies for discussing and addressing BOT
with patients.
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